{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:31:21Z","timestamp":1782603081404,"version":"3.54.5"},"reference-count":63,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The pathologic diagnosis of pleural mesothelioma is generally based on international guidelines, but no compulsory points based on different drugs approvals in different European countries are required to be reported. According to the last (2021) edition of the World Health Organization classification of pleural tumors, the nuclear grade of epithelioid-type mesothelioma should be always inserted in the pathologic report, while the presence of BRCA-associated protein-1 (BAP1) (clone C4) loss and a statement on the presence of the sarcomatoid\/nonepithelioid component are fundamental for both a screening of patients with suspected BAP1 tumor predisposition syndrome and the eligibility to perform first-line immunotherapy at least in some countries. Several Italian experts on pleural mesothelioma who are deeply involved in national scientific societies or dedicated working groups supported by patient associations agreed that the pathology report of mesothelioma of the pleura should always include the nuclear grade in the epithelioid histology, which is an overt statement on the presence of sarcomatoid components (at least 1%, in agreement with the last classification of pleural mesothelioma) and the presence of BAP1 loss (BAP1-deficient mesothelioma) or not (BAP1-retained mesothelioma) in order to screen patients possibly harboring BAP1 tumor predisposition syndrome. This review aims to summarize the most recent data on these three important elements to provide evidence regarding the possible precision needs for mesothelioma.<\/jats:p>","DOI":"10.3390\/jpm14040394","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T10:11:55Z","timestamp":1712571115000},"page":"394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-1218","authenticated-orcid":false,"given":"Giulio","family":"Rossi","sequence":"first","affiliation":[{"name":"Pathology Unit, Services Area, Fondazione Poliambulanza Hospital Institute, Via Bissolati 57, 25124 Brescia, Italy"},{"name":"Fondazione FONICAP, Via Locchi, 26, 37124 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-204X","authenticated-orcid":false,"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barbisan","sequence":"additional","affiliation":[{"name":"Pathological Anatomy Institute, Polytechnic University of Marche Region, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-8465","authenticated-orcid":false,"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma and Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-0596","authenticated-orcid":false,"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[{"name":"Mesothelioma Unit, AO SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-0620","authenticated-orcid":false,"given":"Pasquale","family":"Pisapia","sequence":"additional","affiliation":[{"name":"Department of Public Health, Federico II University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-9957","authenticated-orcid":false,"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[{"name":"Department of Public Health, Federico II University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Sculco","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Dianzani","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Abate-Daga","sequence":"additional","affiliation":[{"name":"TU.TO.R. Tumori Toracici Rari, Patient Advocacy, 20123 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Davolio","sequence":"additional","affiliation":[{"name":"Legal Medicine and Risk Management Department, Azienda Unit\u00e0 Sanitaria Locale di Modena, Strada Martiniana, 21, 41126 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-0629","authenticated-orcid":false,"given":"Giovanni Luca","family":"Ceresoli","sequence":"additional","affiliation":[{"name":"Medical Oncology, Humanitas Gavazzeni Clinic, 24125 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-5906","authenticated-orcid":false,"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[{"name":"Medical Thoracic Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"ref_1","first-page":"20","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.21037\/tlcr-19-620","article-title":"Update on the pathologic diagnosis of malignant mesothelioma","volume":"9","author":"Schulte","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: A multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cncy.22368","article-title":"The \u201cBrescia panel\u201d (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas","volume":"129","author":"Bernardi","year":"2021","journal-title":"Cancer Cytopathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/cyt.13265","article-title":"Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma","volume":"34","author":"Mansour","year":"2023","journal-title":"Cytopathology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/his.15007","article-title":"New developments in mesothelial pathology","volume":"84","author":"Churg","year":"2024","journal-title":"Histopathology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rossi, G., Davoli, F., Poletti, V., Cavazza, A., and Lococo, F. (2021). When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112434"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5858\/arpa.2021-0331-OA","article-title":"A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas","volume":"147","author":"Brcic","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Vrugt, B., Kirschner, M.B., Meerang, M., Oehl, K., Wagner, U., Soltermann, A., Moch, H., Opitz, I., and Wild, P.J. (2023). Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma. Cancers, 15.","DOI":"10.3390\/cancers15204978"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jmoldx.2021.04.002","article-title":"DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics","volume":"23","author":"Bertero","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.18632\/oncotarget.13174","article-title":"Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis","volume":"8","author":"Bruno","year":"2017","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jasc.2022.12.001","article-title":"The cytologic diagnosis of mesothelioma: Are we there yet?","volume":"12","author":"Michael","year":"2022","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/path.5551","article-title":"Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma","volume":"253","author":"Chirieac","year":"2021","journal-title":"J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study","volume":"11","author":"Righi","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zuccatosta, L., Bizzarro, T., Rossi, G., Gallo, G., Gasparini, S., and Ambrosini-Spaltro, A. (2023). Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma. Diagnostics, 13.","DOI":"10.3390\/diagnostics13020249"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ajcp\/aqab091","article-title":"Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma","volume":"157","author":"Terra","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","article-title":"Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis","volume":"146","author":"Cantini","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: Prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pagano, M., Ceresoli, L.G., Zucali, P.A., Pasello, G., Garassino, M., Grosso, F., Tiseo, M., Parra, H.S., Zanelli, F., and Cappuzzo, F. (2020). Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers, 12.","DOI":"10.3390\/cancers12102948"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.21037\/tlcr.2019.11.24","article-title":"BAP1: Role in carcinogenesis and clinical implications","volume":"9","author":"Kobrinski","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sculco, M., La Vecchia, M., Aspesi, A., Clavenna, M.G., Salvo, M., Borgonovi, G., Pittaro, A., Witel, G., Napoli, F., and List\u00ec, A. (2022). Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience. Diagnostics, 12.","DOI":"10.3390\/diagnostics12071710"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41431-023-01448-z","article-title":"Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome","volume":"31","author":"Lalloo","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and Surgical Care of Patients with Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/CCI.20.00124","article-title":"Microsimulation Model for Evaluating the Cost-Effectiveness of Surveillance in BAP1 Pathogenic Variant Carriers","volume":"5","author":"Walpole","year":"2021","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.jtho.2019.07.002","article-title":"Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations","volume":"14","author":"Zauderer","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/hmg\/ddz076","article-title":"Population-based analysis of BAP1 germline variations in patients with uveal melanoma","volume":"28","author":"Repo","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/hmg\/ddad193","article-title":"Functional assay for assessment of pathogenicity of BAP1 variants","volume":"33","author":"Repo","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tompson, S.W., and Young, T.L. (2017). Assaying the Effects of Splice Site Variants by Exon Trapping in a Mammalian Cell Line. Bio-Protocol, 7.","DOI":"10.21769\/BioProtoc.2281"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/gcc.22218","article-title":"Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area","volume":"54","author":"Betti","year":"2015","journal-title":"Genes, Chromosom. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: Not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/PAS.0000000000001854","article-title":"A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma with a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS)","volume":"46","author":"Fuchs","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/cncy.22705","article-title":"Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting","volume":"131","author":"Li","year":"2023","journal-title":"Cancer Cytopathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/cyt.12996","article-title":"The value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)","volume":"33","author":"Straccia","year":"2022","journal-title":"Cytopathology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000501536","article-title":"Announcement: The International System for Reporting Serous Fluid Cytopathology","volume":"63","author":"Chandra","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtho.2023.08.004","article-title":"Meta-Analysis on the Combination of Chemotherapy with Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma","volume":"19","author":"Tagliamento","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-pathol-042420-092719","article-title":"Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment","volume":"19","author":"Fanaroff","year":"2024","journal-title":"Annu. Rev. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center","volume":"13","author":"Salle","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/apm.13203","article-title":"Spindle cell tumors of the pleura and the peritoneum: Pathologic diagnosis and updates","volume":"130","author":"Boyraz","year":"2022","journal-title":"APMIS"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1002\/cncr.32416","article-title":"Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma","volume":"125","author":"Chirieac","year":"2019","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jtho.2019.11.011","article-title":"Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults with Mesothelioma","volume":"15","author":"Mian","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/PAS.0000000000001469","article-title":"HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma","volume":"44","author":"Naso","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lennartz, M., Atug, D., Rico, S.D., Reiswich, V., Viehweger, F., B\u00fcscheck, F., Kluth, M., Hube-Magg, C., Hinsch, A., and Bernreuther, C. (2022). Analysis of More than 16,000 Human Tumor and Normal Tissues Identifies Uroplakin 3B as a Useful Diagnostic Marker for Mesothelioma and Normal Mesothelial Cells. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102516"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/his.14783","article-title":"Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases","volume":"82","author":"Churg","year":"2023","journal-title":"Histopathology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/1759-7714.14827","article-title":"Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations","volume":"14","author":"Sejben","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00428-020-02980-9","article-title":"Challenges in lung and thoracic pathology: Molecular advances in the classification of pleural mesotheliomas","volume":"478","author":"Mangiante","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00428-022-03355-y","article-title":"Correction to: Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition","volume":"481","author":"Napoli","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.32074\/1591-951X-868","article-title":"The slow-paced digital evolution of pathology: Lights and shadows from a multifaceted board","volume":"115","author":"Caputo","year":"2023","journal-title":"Pathologica"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/4\/394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:04Z","timestamp":1760106304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/4\/394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jpm14040394"],"URL":"https:\/\/doi.org\/10.3390\/jpm14040394","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}